Peptide And Oligonucleotide CDMO Market Report 2026

Peptide And Oligonucleotide CDMO Market Overview

• Peptide And Oligonucleotide CDMO market size has reached to $2.42 billion in 2025 • Expected to grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Personalized Medicine Drives Growth In Peptide And Oligonucleotide CDMO Market • Market Trend: Strategic Partnerships In Peptide And Oligonucleotide CDMO Market Boost Technological Capabilities And Market Reach • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Peptide And Oligonucleotide CDMO Market?

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that provides services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations offer expertise in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to support the production of peptides and oligonucleotides for various companies. The main product types of peptides and oligonucleotide CDMO included are peptides and oligonucleotides. Peptides are short chains of amino acids, typically less than 50 amino acids in length, that play crucial roles in biological processes such as signaling and hormone regulation. It provides services such as contract development, and contract manufacturing. These have applications in therapeutics, research applications, diagnostics, and others, and are used by end-users such as biopharmaceutical companies, pharmaceutical companies, research institutes, academic and government organizations, and others.

What Is The Peptide And Oligonucleotide CDMO Market Growth Forecast?

The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of oligonucleotide therapeutics pipelines, increasing investment in rare disease and oncology drugs, rising demand for rapid clinical trial material production, growing preference for specialized cdmo partnerships, advancements in solid-phase synthesis technologies. Major trends in the forecast period include rising outsourcing of peptide and oligonucleotide manufacturing, growing demand for cgmp-compliant complex molecule production, expansion of end-to-end development and manufacturing services, increased focus on high-potency and high-purity therapeutics, greater adoption of scalable and flexible manufacturing platforms.

Global Peptide And Oligonucleotide CDMO Market Segmentation

1) By Product: Peptides, Oligonucleotides 2) By Service Type: Contract Development, Contract Manufacturing, 3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications 4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users Subsegments: 1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services 2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

What Is The Driver Of The Peptide And Oligonucleotide CDMO Market?

The growing adoption of personalized medicine is expected to propel the growth of the peptide and oligonucleotide CDMO markets going forward. Personalized medicine is an approach to healthcare that tailors medical decisions and treatments to individual characteristics, such as genetics, environment, and lifestyle. The growing adoption of personalized medicine is due to several factors such as advancements in genomic technologies, increased understanding of disease mechanisms at the molecular level, and the demand for more effective and targeted treatment options tailored to individual patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a crucial role in personalized medicine by producing customized therapeutic peptides and oligonucleotides tailored to individual patient needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the peptide and oligonucleotide CDMO industry.

Key Players In The Global Peptide And Oligonucleotide CDMO Market

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Global Peptide And Oligonucleotide CDMO Market Trends and Insights

Major companies operating in the peptide and oligonucleotide CDMO market are focusing on developing strategic partnerships to enhance their service offerings, expand their technological capabilities, and increase their market reach. Peptide development and production partnerships refer to collaborative agreements between two organizations focused on developing and manufacturing peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), partnered with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This partnership aims to utilize PolyPeptide's cGMP manufacturing capacities and market access, along with Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is focused on jointly exploring the development of suitable peptide candidates with the goal of more sustainable production of peptide-based APIs.

What Are Latest Mergers And Acquisitions In The Peptide And Oligonucleotide CDMO Market?

In May 2024, EUROAPI, a France-based contract development and manufacturing organization, acquired BianoGMP for an undisclosed amount. This acquisition was aimed to bolster EUROAPI's position in the contract development and manufacturing organization (CDMO) market for oligonucleotides, complementing its current capacity in Frankfurt. BianoGMP is a Germany-based contract development and manufacturing organization (CDMO) specializing in providing analytical services for oligonucleotides.

Regional Insights

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Peptide And Oligonucleotide CDMO Market?

The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Peptide And Oligonucleotide CDMO Market Report 2026?

The peptide and oligonucleotide cdmo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide cdmo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.